KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Assets (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Assets for 16 consecutive years, with $90.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Assets fell 2.77% to $90.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $90.0 billion, a 2.77% decrease, with the full-year FY2025 number at $90.0 billion, down 2.77% from a year prior.
  • Assets was $90.0 billion for Q4 2025 at Bristol Myers Squibb, down from $92.4 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $112.4 billion in Q1 2021 to a low of $90.0 billion in Q4 2025.
  • A 4-year average of $99.9 billion and a median of $98.6 billion in 2022 define the central range for Assets.
  • Peak YoY movement for Assets: dropped 11.66% in 2021, then dropped 2.77% in 2025.
  • Bristol Myers Squibb's Assets stood at $109.3 billion in 2021, then fell by 11.43% to $96.8 billion in 2022, then decreased by 4.36% to $92.6 billion in 2024, then decreased by 2.77% to $90.0 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Assets are $90.0 billion (Q4 2025), $92.4 billion (Q1 2025), and $92.6 billion (Q4 2024).